Benutzer: Gast  Login
Titel:

Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO.

Dokumenttyp:
Article; Journal Article
Autor(en):
Kubasch, Anne Sophie; Giagounidis, Aristoteles; Metzgeroth, Georgia; Jonasova, Anna; Herbst, Regina; Diaz, Jose Miguel Torregrosa; De Renzis, Benoit; Götze, Katharina S; Huetter-Kroenke, Marie-Luise; Gourin, Marie-Pierre; Slama, Borhane; Dimicoli-Salazar, Sophie; Cony-Makhoul, Pascale; Laribi, Kamel; Park, Sophie; Jersemann, Katja; Schipp, Dorothea; Metzeler, Klaus H; Tiebel, Oliver; Sockel, Katja; Gloaguen, Silke; Mies, Anna; Chermat, Fatiha; Thiede, Christian; Sapena, Rosa; Schlenk, Richard F;...     »
Abstract:
The EUROPE phase 2 trial investigated the predictive value of biomarkers on the clinical efficacy of single agent romiplostim (ROM) treatment in patients with lower-risk myelodysplastic neoplasms (LR-MDS) and thrombocytopenia within the 'European Myelodysplastic Neoplasms Cooperative Group' (EMSCO) network. A total of 77 patients with LR-MDS and a median platelet count of 25/nl were included, all patients received ROM at a starting dose of 750 μg by SC injection weekly. Thirty-two patients (42%)...     »
Zeitschriftentitel:
Leukemia
Jahr:
2022
Band / Volume:
36
Heft / Issue:
10
Seitenangaben Beitrag:
2519-2527
Volltext / DOI:
doi:10.1038/s41375-022-01669-z
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/36071100
Print-ISSN:
0887-6924
TUM Einrichtung:
Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie
 BibTeX